Cohance Lifesciences reported a weak start to FY27. The company posted a consolidated net loss of ₹24.1 crore in the April-June quarter, compared with a ₹48.9 crore net profit in the same period last year. Revenue from operations also declined 23.1% year-on-year to ₹422 crore, while operating performance weakened sharply with EBITDA declining 99% to ₹1.2 crore.